Product news

Share this article:

Sciele Pharma expaned its alliance with Sanofi-Aventis with a new exclusive, three-year agreement to market Allegra orally disintegrating tablets (ODT) and Allegra oral suspension in the pediatric market in the US. Under terms of the deal, Sciele will be responsible for all sales and marketing programs associated with the products in the US and will share revenues on both Allegra OS and ODT. Sciele expects to launch Allegra ODT in March 2008 through its 100 pediatric sales representatives.

Hisamitsu Pharmaceutical Co. obtained FDA approval for its topical analgesic product, Salonpas pain relief patch code-named FS-67.The product contains methyl salicylate and l-menthol as active ingredients and will be marketed as an OTC topical pain-reliever under the names of Salonpas  pain relief patch and Salonpas arthritis pain by Hisamitsu America.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.